ValuEngine Lowers Becton Dickinson and (NYSE:BDX) to Hold

ValuEngine downgraded shares of Becton Dickinson and (NYSE:BDX) from a buy rating to a hold rating in a research note released on Thursday, ValuEngine reports.

Several other research firms have also weighed in on BDX. Zacks Investment Research raised shares of Becton Dickinson and from a sell rating to a hold rating in a report on Monday, May 20th. Wells Fargo & Co cut their target price on shares of Becton Dickinson and from $280.00 to $265.00 and set an outperform rating on the stock in a report on Monday, May 13th. KeyCorp restated an overweight rating and set a $262.00 price objective (down from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Barclays upgraded shares of Becton Dickinson and from an equal weight rating to an overweight rating and set a $266.00 price target on the stock in a research note on Monday, May 13th. Finally, Raymond James lifted their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a strong-buy rating in a research report on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $265.00.

NYSE:BDX traded down $7.22 during trading hours on Thursday, hitting $241.47. 27,631 shares of the stock traded hands, compared to its average volume of 816,174. The business’s 50 day simple moving average is $250.17. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $265.87. The firm has a market capitalization of $67.08 billion, a price-to-earnings ratio of 21.91, a price-to-earnings-growth ratio of 1.84 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. During the same period in the prior year, the company posted $2.65 earnings per share. Becton Dickinson and’s revenue for the quarter was down .6% on a year-over-year basis. Equities analysts anticipate that Becton Dickinson and will post 11.68 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.28%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total transaction of $687,836.82. Following the transaction, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the transaction, the executive vice president now directly owns 12,608 shares in the company, valued at $2,958,845.44. The disclosure for this sale can be found here. Insiders sold 21,154 shares of company stock valued at $4,955,775 over the last 90 days. 0.12% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its stake in Becton Dickinson and by 2,353.8% in the 2nd quarter. Meeder Asset Management Inc. now owns 319 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 306 shares in the last quarter. K.J. Harrison & Partners Inc raised its position in Becton Dickinson and by 3.6% in the 2nd quarter. K.J. Harrison & Partners Inc now owns 14,300 shares of the medical instruments supplier’s stock worth $3,604,000 after buying an additional 500 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at about $2,062,000. Oakworth Capital Inc. increased its position in shares of Becton Dickinson and by 9.0% during the 2nd quarter. Oakworth Capital Inc. now owns 1,858 shares of the medical instruments supplier’s stock valued at $468,000 after purchasing an additional 154 shares during the last quarter. Finally, Usca Ria LLC purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at about $674,000. Institutional investors and hedge funds own 84.85% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: How Does the Quiet Period Work?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.